Trial Profile
Romidepsin in patients with relapsed of refractory peripheral T-cell lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2014
Price :
$35
*
At a glance
- Drugs Romidepsin (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Therapeutic Use
- 02 Feb 2014 New trial record
- 10 Dec 2013 Results assessing outcomes in patients aged 60 years or older presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.